Polivy Archives -

The FDA has started a review of Roche’s Polivy for people with previously untreated diffuse large B-cell lymphoma

Roche eyes April FDA verdict on Polivy as first-line lymphoma therapy

https://pharmaphorum.com/news/roche-eyes-april-fda-verdict-on-polivy-as-first-line-lymphoma-therapy/

Roche will present the new data at next week’s ASCO congress showing that its bispecific antibody glofitamab can

Roche trumpets new glofitamab data in lymphoma at ASCO

https://pharmaphorum.com/news/roche-trumpets-new-glofitamab-data-in-lymphoma-at-asco/

Roche has moved a step closer to extending the use of its B-cell lymphoma therapy Polivy into the

Roche closes in on first-line use for lymphoma drug Polivy in Europe

https://pharmaphorum.com/news/roche-closes-in-on-first-line-use-for-lymphoma-drug-polivy-in-europe/

Roche trumpeted a top-line results of the POLARIX trial of its Polivy therapy in previously-untreated B-cell lymphoma, and

ASH abstract drop backs Roche’s Polivy in first-line lymphoma

https://pharmaphorum.com/news/ash-abstract-drop-backs-roches-polivy-in-first-line-lymphoma/

Roche has the results it was hoping for in a phase 3 trial of Polivy in newly diagnosed

Armed with phase 3 data, Roche preps filing for Polivy in first-line DLBCL

https://pharmaphorum.com/news/armed-with-ph3-trial-roche-preps-filing-for-polivy-in-first-line-dlbcl/

NHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug

After a nay from NICE, Scotland says aye to J&J’s Spravato

https://pharmaphorum.com/news/after-a-nay-from-nice-scotland-says-aye-to-jjs-spravato/

NICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning

NICE recommends regular NHS funding for Roche’s lymphoma drug Polivy

https://pharmaphorum.com/news/nice-recommends-regular-nhs-funding-for-roches-lymphoma-drug-polivy/

The EMA’s human medicines advisory committee recommended approval of five novel medicines at its November meeting, including Novartis’

Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvals

https://pharmaphorum.com/news/novartis-mayzent-roches-polivy-head-latest-crop-of-chmp-approvals/

Polivy